US5403834A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
Assignee: Lucas Meyer Cosmetics Canada Inc
•
Filing: 1992-12-07
•
Granted: 1995-04-04
•
Expires: 2012-12-07
Abstract
Abstract The invention provides antioxidant salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide.
Inventors
- 👤 Bernard Malfroy-Camine
- 👤 Michel Baudry
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 10:46
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/28; A61K31/33; A61K31/555; A61P; A61P25/00; A61P3/00; A61P39/00; A61P39/06; A61P9/00; A61P9/08; A61P9/10; C; C07; C07F; C07F13/00; C07F13/005
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
151 words
A pharmaceutical composition comprising a therapeutically effective dose of an antioxidant salen-metal complex in a pharmaceutically acceptable form, wherein the antioxidant salen-metal complex has the structural formula ##STR15## wherein M is manganese; A is H or halogen; n is 0, 4, 5, or 6, wherein Cn is absent if n=0 and is a saturated hydrocarbon chain if n=4, 5, or 6; R 1 and R 4 are independently selected from the group consisting of H, phenyl, lower alkoxy, and lower fatty acid esters; X 1 and X 3 are independently selected from the group consisting of H, lower alkyl, amine, lower alkylamino, and halogen; X 2 and X 4 are H; Y 1 and Y 4 are independently selected from the group consisting of H, lower alkyl, halogen, and lower alkoxy; Y 2 , Y 3 , Y 5 and Y 6 are H; and all remaining substituent positions are H.
Claim 2
Dependent Claim
151 words
A pharmaceutical composition comprising a therapeutically effective dose of an antioxidant salen-metal complex in a pharmaceutically acceptable form, wherein the antioxidant salen-metal complex has the structural formula ##STR15## wherein M is manganese; A is H or halogen; n is 0, 4, 5, or 6, wherein Cn is absent if n=0 and is a saturated hydrocarbon chain if n=4, 5, or 6; R 1 and R 4 are independently selected from the group consisting of H, phenyl, lower alkoxy, and lower fatty acid esters; X 1 and X 3 are independently selected from the group consisting of H, lower alkyl, amine, lower alkylamino, and halogen; X 2 and X 4 are H; Y 1 and Y 4 are independently selected from the group consisting of H, lower alkyl, halogen, and lower alkoxy; Y 2 , Y 3 , Y 5 and Y 6 are H; and all remaining substituent positions are H.
Claim 3
Dependent Claim
20 words
A pharmaceutical composition according to claim 1 wherein the antioxidant salen-metal complex is selected from the group consisting of: ##STR16##
Claim 4
Dependent Claim
31 words
A pharmaceutical composition comprising a therapeutically effective dose of an antioxidant salen-metal complex in a pharmaceutically acceptable form, wherein the antioxidant salen-metal complex is selected from the group consisting of: ##STR17##
Claim 5
Dependent Claim
31 words
A pharmaceutical composition comprising a therapeutically effective dose of an antioxidant salen-metal complex in a pharmaceutically acceptable form, wherein the antioxidant salen-metal complex is selected from the group consisting of: ##STR17##
Claim 6
Dependent Claim
31 words
A pharmaceutical composition comprising a therapeutically effective dose of an antioxidant salen-metal complex in a pharmaceutically acceptable form, wherein the antioxidant salen-metal complex is selected from the group consisting of: ##STR18##
Claim 7
Dependent Claim
31 words
A pharmaceutical composition comprising a therapeutically effective dose of an antioxidant salen-metal complex in a pharmaceutically acceptable form, wherein the antioxidant salen-metal complex is selected from the group consisting of: ##STR18##
Claim 8
Dependent Claim
16 words
A pharmaceutical composition according to claim 3, wherein the antioxidant salen-metal complex is the SOD-mimetic ##STR19##
Claim 9
Dependent Claim
25 words
A pharmaceutical composition according to claim 5, wherein the pharmaceutical composition comprises at least 10 mg of ##STR20## in a form suitable for parenteral administration.
References Cited (Backward Citations)
US5106841A
Cited
US5223538A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-04-03 | 1998-10-03 | 1999-04-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-04-03 | 2002-10-03 | 2003-04-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-04-03 | 2006-10-03 | 2007-04-04 | $7700.00 | Window Closed / Lapsed |